Kiniksa Pharmaceuticals International Plc share price logo

Kiniksa Pharmaceuticals International Plc Share Price

NASDAQ: KNSA

Small Cap

$37.08

+0.07

(+0.19%)

as on

Kiniksa Pharmaceuticals International Plc Stock Performance

as on September 13, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $36.4
    $37.34
    downward going graph

    1.83%

    Downside

    0.70%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $17.82
    $37.25
    downward going graph

    51.94%

    Downside

    0.46%

    Upside

    downward going graph

Kiniksa Pharmaceuticals International Plc share price movements today

Previous Close
$37.01
Open
$37.06
Volume
422.0K
Day's Low - High
$36.4 - $37.34
52 Week Low - High
$17.82 - $37.25

Kiniksa Pharmaceuticals International Plc Historical Returns

1 Month Return
+ 12.9 %
3 Month Return
+ 33.47 %
1 Year Return
+ 51.12 %
3 Year Return
+ 235.54 %
5 Year Return
+ 133.06 %

Kiniksa Pharmaceuticals International Plc Stock Fundamentals & Key Indicators

Check Kiniksa Pharmaceuticals International Plc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.7B

EPS (TTM)

1.2401

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

5.50%

PE Ratio (TTM)

740.2

Industry PE ratio

-3.9597814207650273

P/B Ratio

740.2

PEG Ratio

0

EBITDA

6.0M

Revenue (TTM)

529.3M

Profit Margin

0.90%

Return On Equity TTM

1.03%

Kiniksa Pharmaceuticals International Plc Stock Valuation

Track how Kiniksa Pharmaceuticals International Plc P/E has moved over time to understand its valuation trends.

Kiniksa Pharmaceuticals International Plc in the last 5 years

  • Overview

  • Trends

Lowest (4.09x)

June 30, 2023

Industry (-3.96x)

September 12, 2025

Today (740.20x)

September 12, 2025

Highest (177.55x)

March 31, 2024

LowHigh

Today’s Price to Earnings Ratio: 740.20x

Kiniksa Pharmaceuticals International Plc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kiniksa Pharmaceuticals International Plc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$2.7B133.06%740.20.90%
BUY$18.3BNA15.8140.36%
BUY$44.2BNA21.9313.81%
BUY$14.2B43.04%42.6113.88%
BUY$66.7B-5.03%25.9227.83%

Stock Returns calculator for Kiniksa Pharmaceuticals International Plc Stock including INR - Dollar returns

The Kiniksa Pharmaceuticals International Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Kiniksa Pharmaceuticals International Plc investment value today

Current value as on today

₹1,56,524

Returns

₹56,524

(+56.52%)

Returns from Kiniksa Pharmaceuticals International Plc Stock

₹51,409 (+51.41%)

Dollar Returns*

₹5,115 (+5.12%)

Analyst Recommendation on Kiniksa Pharmaceuticals International Plc Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Kiniksa Pharmaceuticals International Plc. Average target price of $46.5

Kiniksa Pharmaceuticals International Plc Share Price Target

Get share price movements and forecasts by analysts on Kiniksa Pharmaceuticals International Plc.

What analysts predicted

20.26%UPSIDE

Target Price

$46.5

Current Price

$37.08

Analyzed by

11 Analysts

Target

$46.50

Kiniksa Pharmaceuticals International Plc target price $46.5, a slight upside of 20.26% compared to current price of $37.08. According to 11 analysts rating.

Kiniksa Pharmaceuticals International Plc Stock's Interest Amongst Investors

Search interest for Kiniksa Pharmaceuticals International Plc Stock has decreased by -8% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-8% versus previous 30 day period

Kiniksa Pharmaceuticals International Plc Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
48
71
67
83
79
108
112
122
137
156
Gross Profit
41
49
40
56
48
66
62
184
76
85
Operating Income
-11
-3
-10
0
-16
0
-9
-19
13
20
EBITDA
-10
-2
-10
0
-16
0
-9
-18
13
20
Interest Expense
1
-
-
1
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-9
-1
-8
2
-14
2
-7
-16
15
22
Income Tax Expense
2
-16
5
-22
3
6
5
-8
7
-5
Net Income
-12
14
-13
25
-17
-3
-12
-8
8
17
Net Profit Margin
-25.38%
20.95%
-20.66%
30.26%
-22.17%
-3.60%
-11.31%
-7.25%
6.20%
11.37%

Kiniksa Pharmaceuticals International Plc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-
-
7
38
220
270
423
Gross Profit
0
0
0
-3
-3
29
173
213
362
Operating Income
-24
-65
-108
-169
-157
-156
7
-25
-45
EBITDA
-23
-65
-107
-167
-154
-154
9
-22
-45
Interest Expense
-
-
-
8
3
2
1
-
-
Depreciation
-
0
0
2
2
2
2
2
1
Income Before Tax
-23
-64
-103
-163
-156
-156
11
-16
-36
Income Tax Expense
0
0
0
-2
5
1
-172
-30
7
Net Income
-23
-64
-103
-161
-161
-157
183
14
-43
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
-2094.77%
-409.72%
83.28%
5.21%
-10.21%

Kiniksa Pharmaceuticals International Plc Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
14
-13
25
-17
-3
-12
-8
8
17
Operating Cash Flow
-3
16
4
3
5
-2
18
22
28
Investing Cash Flow
35
-12
-14
25
-46
-6
65
-51
-3
Financing Cash Flow
0
0
0
3
0
6
2
2
10
Change in Cash
31
5
-9
33
-41
-1
86
-26
34

Kiniksa Pharmaceuticals International Plc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-64
-103
-161
-161
-157
183
14
-43
Operating Cash Flow
-50
-81
-158
-136
-126
5
13
25
Investing Cash Flow
0
-239
49
-23
128
-8
-29
37
Financing Cash Flow
39
346
84
227
5
2
1
12
Change in Cash
-10
26
-25
67
8
0
-14
75

Global Institutional Holdings in Kiniksa Pharmaceuticals International Plc

Funds
Holdings
BlackRock Inc
4.63%
Rubric Capital Management LP
4.57%
Vanguard Group Inc
4.53%
Baker Bros Advisors LP
3.8%
TANG CAPITAL MANAGEMENT LLC
2.86%

Insights on Kiniksa Pharmaceuticals International Plc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, KNSA stock has moved up by 250.8%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 6 quarters, 79.85M → 156.79M (in $), with an average increase of 12.3% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 4 quarters, -12.69M → 17.83M (in $), with an average increase of 99.7% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, KNSA has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, KNSA has outperformed top 5 stocks with highest market-cap in its industry

About Kiniksa Pharmaceuticals International Plc

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
OrganisationKiniksa Pharmaceuticals International Plc
Headquarters23 Old Bond Street, London, United Kingdom, WIS 4PZ
IndustryHealth Technology
CEOMr. Sanj K. Patel
E-voting on sharesClick here to vote

Key Management of Kiniksa Pharmaceuticals International Plc

Name

Title

Mr. Sanj K. Patel

CEO & Chairman of the Board

Mr. Eben Tessari

Executive VP & COO

Dr. John F. Paolini FACC, M.D., Ph.D.

Executive VP & Chief Medical Officer

Mr. Ross Michael Moat

Executive VP & Chief Commercial Officer

Mr. Michael R. Megna CPA

Chief Accounting Officer & Group VP of Finance

Ms. Mei Jang

Senior Vice President of Technical Operations

Jonathan Kirshenbaum

Investor Relations Officer

Ms. Megan Woods M.B.A.

Senior VP & Chief Human Resources Officer

Ms. Martina Struck Ph.D.

Senior Vice President of Regulatory Affairs

Mr. Mark A. Ragosa C.F.A.

Senior VP & CFO

FAQs

What is Kiniksa Pharmaceuticals International Plc share price today?

Kiniksa Pharmaceuticals International Plc share price today is $37.08 as on at the close of the market. Kiniksa Pharmaceuticals International Plc share today touched a day high of $37.34 and a low of $36.4.

What is the 52 week high and 52 week low for Kiniksa Pharmaceuticals International Plc share?

Kiniksa Pharmaceuticals International Plc share touched a 52 week high of $37.25 on and a 52 week low of $17.82 on . Kiniksa Pharmaceuticals International Plc stock price today i.e. is closed at $37.08,which is 0.46% down from its 52 week high and 108.08% up from its 52 week low.

What is Kiniksa Pharmaceuticals International Plc's market capitalisation today?

Kiniksa Pharmaceuticals International Plc market capitalisation is $0.00T as on .

How to invest in Kiniksa Pharmaceuticals International Plc Stock (KNSA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Kiniksa Pharmaceuticals International Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kiniksa Pharmaceuticals International Plc Shares that will get you 0.0405 shares as per Kiniksa Pharmaceuticals International Plc share price of $37.08 per share as on September 13, 2025 at 1:29 am IST.

What is the minimum amount required to buy Kiniksa Pharmaceuticals International Plc Stock (KNSA) from India?

Indian investors can start investing in Kiniksa Pharmaceuticals International Plc (KNSA) shares with as little as ₹88.25 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹882.50 in Kiniksa Pharmaceuticals International Plc stock (as per the Rupee-Dollar exchange rate as on ). Based on Kiniksa Pharmaceuticals International Plc share’s latest price of $37.08 as on September 13, 2025 at 1:29 am IST, you will get 0.2697 shares of Kiniksa Pharmaceuticals International Plc. Learn more about fractional shares .

What are the returns that Kiniksa Pharmaceuticals International Plc has given to Indian investors in the last 5 years?

Kiniksa Pharmaceuticals International Plc stock has given 133.06% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?